The ALOX5 variants that confer susceptibility to asthma, therefore, may be of pharmacogenetic significance if an inadequate quantity of ALOX5 protein is available as a drug target (Lima et al., 2006; Telleria et al., 2008; Tantisira et al., 2009). This evidence concerns the gene ALOX5 and asthma.